Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | DR-0201 |
Synonyms | |
Therapy Description |
Limited information is currently available on DR-0201, a putative bispecific antibody targeting a phagocytic receptor on myeloid cells (May 2024). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
DR-0201 | DR 0201|DR0201 | Limited information is currently available on DR-0201, a putative bispecific antibody targeting a phagocytic receptor on myeloid cells (May 2024). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06392477 | Phase I | DR-0201 | A Study of DR-0201 in Subjects With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma | Recruiting | AUS | 5 |